Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mink Therapeutics Inc (NQ: INKT ) 0.7090 -0.0050 (-0.70%) Streaming Delayed Price Updated: 3:52 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mink Therapeutics Inc < Previous 1 2 3 4 Next > MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors October 31, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors October 08, 2024 From MiNK Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session October 04, 2024 Via Benzinga Earnings Outlook For MiNK Therapeutics March 20, 2024 Via Benzinga MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 October 04, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference September 03, 2024 From MiNK Therapeutics Via GlobeNewswire INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024 August 13, 2024 INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace MiNK Reports Second Quarter 2024 Results and Business Update August 13, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report August 01, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement July 31, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Therapeutics Announces Virtual Annual Shareholders Meeting June 05, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting May 22, 2024 From MiNK Therapeutics Via GlobeNewswire INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024 May 14, 2024 INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace MiNK Reports First Quarter 2024 Results May 14, 2024 From MiNK Therapeutics Via GlobeNewswire Why MiNK Therapeutics Stock Is Up 11% Monday May 13, 2024 MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session May 13, 2024 Via Benzinga MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer May 13, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK to Provide Corporate Update and First Quarter 2024 Financial Report April 30, 2024 From MiNK Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session April 08, 2024 Via Benzinga MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR April 08, 2024 From MiNK Therapeutics Via GlobeNewswire Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session April 05, 2024 Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session April 05, 2024 Via Benzinga INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 March 21, 2024 INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace MiNK Reports Fourth Quarter and Year-End 2023 Results March 21, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report March 07, 2024 From MiNK Therapeutics Via GlobeNewswire Earnings Scheduled For March 21, 2024 March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Via Benzinga MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 March 06, 2024 MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model From MiNK Therapeutics Via GlobeNewswire First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab February 14, 2024 From MiNK Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session February 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 06, 2024 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
